Mesirow Financial Investment Management - Fixed Income’s Myriad Genetics MYGN Stock Holding History

Mesirow Financial Investment Management - Fixed Income’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-167,610	Closed	-$5.57M	–	131
2019 Q1	$5.57M	Sell	167,610 -139,935	-46%	-$4.26M	0.86%	68
2018 Q4	$8.94M	Sell	307,545 -61,810	-17%	-$2.22M	1.2%	42
2018 Q3	$17M	Sell	369,355 -30,070	-8%	-$1.34M	1.54%	12
2018 Q2	$14.9M	Buy	+399,425	New	+$13.5M	1.37%	22

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Mesirow Financial Investment Management - Fixed Income's MYGN Position: Q2 2019 in Review

Mesirow Financial Investment Management - Fixed Income sold out of Myriad Genetics (MYGN) in Q2 2019, closing a stake of 167,610 shares — an estimated $5.57M sold.

Mesirow Financial Investment Management - Fixed Income first reported a position in MYGN in Q2 2018 and held it in 4 quarters. The position peaked at $17M in Q3 2018. 235 funds tracked by Wall St. Rank hold MYGN as of Q2 2019.

Mesirow Financial Investment Management - Fixed Income reported no remaining Myriad Genetics position as of Q2 2019 after selling out during the quarter.
Mesirow Financial Investment Management - Fixed Income sold 167,610 Myriad Genetics shares in Q2 2019, an estimated $5.57M.
Mesirow Financial Investment Management - Fixed Income first reported a position in Myriad Genetics in Q2 2018 and held it in 4 quarters.
Mesirow Financial Investment Management - Fixed Income's Myriad Genetics position peaked at $17M in Q3 2018.
235 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2019.

Based on Mesirow Financial Investment Management - Fixed Income's 13F filing for Q2 2019, filed 30 Jul 2019.